Table 1.
Baseline characteristics of cancer patients with COVID-19.
| Characteristics | Overalln = 68 | Survivorsn = 43 | Non-survivorsn = 25 | p-value |
|---|---|---|---|---|
| Age at diagnosis | 0.001 | |||
| Median | 72 (23–91) | 67 (23–88) | 77 (56–91) | |
| < 75 | 40 (58.8) | 32 (74.4) | 8 (32.0) | |
| ≥ 75 | 28 (41.2) | 11 (25.6) | 17 (68.0) | |
| Gender | 0.086 | |||
| Male | 37 (54.4) | 20 (46.5) | 17 (68.0) | |
| Female | 31 (45.6) | 23 (53.5) | 8 (32.0) | |
| Race/Ethnicity | 0.54 | |||
| White | 23 (33.8) | 15 (34.9) | 8 (32.0) | |
| Black | 36 (52.9) | 21 (48.8) | 15 (60.0) | |
| Other | 9 (13.2) | 7 (16.3) | 2 (8.0) | |
| Obesity status | 0.52 | |||
| Normal | 24 (35.3) | 13 (30.2) | 11 (44.0) | |
| Overweight (BMI 25–29.9) | 25 (36.8) | 17 (39.5) | 8 (32.0) | |
| Obese (≥ 30) | 19 (27.9) | 13 (30.2) | 6 (24.0) | |
| Comorbidity Score | 0.004 | |||
| ≤ 3 | 29 (42.6) | 24 (55.8) | 5 (20.0) | |
| > 3 | 39 (57.4) | 19 (44.2) | 20 (80.0) | |
| Smoking status | 0.057 | |||
| Never smoked | 44 (64.7) | 32 (74.4) | 12 (48.0) | |
| Former smoker | 20 (29.4) | 10 (23.3) | 10 (40.0) | |
| Current smoker | 4 (5.9) | 1 (2.3) | 3 (12.0) | |
| Type of malignancy | 0.74 | |||
| Breast | 15 (22.1) | 12 (27.9) | 3 (12.0) | |
| Prostate | 12 (17.6) | 8 (18.6) | 4 (16.0) | |
| Lung | 8 (11.8) | 4 (9.3) | 4 (16.0) | |
| Colon | 7 (10.3) | 5 (11.6) | 2 (8.0) | |
| Renal | 5 (7.4) | 2 (4.7) | 3 (12.0) | |
| CNS | 4 (5.9) | 3 (7.0) | 1 (4.0) | |
| Melanoma | 3 (4.4) | 2 (4.7) | 1 (4.0) | |
| Hematologic | 8 (11.8) | 4 (9.3) | 4 (16.0) | |
| Others | 6 (8.8) | 3 (7.0) | 3 (12.0) | |
| Insurance status | 0.002 | |||
| Medicare Original | 15 (22.1) | 7 (16.3) | 8 (32.0) | |
| Medicare MGD | 33 (48.5) | 17 (39.5) | 16 (64.0) | |
| Others | 20 (29.4) | 19 (44.2) | 1 (4.0) | |
| Self-pay/Charity | 2 (2.9) | 2 (4.7) | 0 (0.0) | |
| Medicaid | 4 (5.9) | 3 (6.9) | 1 (4.0) | |
| Commercial | 8 (11.8) | 8 (18.6) | 0 (0.0) | |
| Managed care | 6 (8.8) | 6 (14.0) | 0 (0.0) | |
| ECOG performance status | <0.001 | |||
| 0–2 | 35 (51.5) | 35 (81.4) | 0 (0.0) | |
| 3 | 25 (36.8) | 6 (14.0) | 19 (76.0) | |
| 4 | 8 (11.8) | 2 (4.7) | 6 (24.0) | |
| Anti-cancer therapy | 0.097 | |||
| None in the 4 weeks before COVID-19 diagnosis | 46 (67.6) | 26 (60.5) | 20 (80.0) | |
| Within 4 weeks before COVID-19 diagnosis | 22 (32.4) | 17 (39.5) | 5 (20.0) | |
| Systemic chemotherapy | 13 (19.1) | 9 (20.9) | 4 (16.0) | |
| Radiotherapy | 2 (2.9) | 2 (4.7) | 0 (0) | |
| Hormonotherapy | 6 (8.8) | 5 (11.6) | 1 (4.0) | |
| Immunotherapy | 1 (1.5) | 1 (2.3) | 0 (0) | |
| Treatment of COVID-19 | ||||
| Remdesivir | 16 (23.5) | 13 (30.2) | 3 (12.0) | 0.087 |
| Conv plasma | 15 (22.1) | 11 (25.6) | 4 (16.0) | 0.35 |
| Toculizimab | 3 (4.4) | 2 (4.7) | 1 (4.0) | 0.90 |
| Dexamethasone | 17 (25.0) | 16 (37.2) | 1 (4.0) | 0.002 |
| Methylprednisolone | 20 (29.4) | 10 (23.3) | 10 (40) | 0.14 |
| Hydroxychloroquine | 10 (14.7) | 4 (9.3) | 6 (24.0) | 0.09 |
| Azithromycin | 17 (25.0) | 9 (20.9) | 8 (32.0) | 0.30 |
| Oxygen requirement | <0.001 | |||
| Room air or Up to 6 L | 33 (48.5) | 30 (69.8) | 3 (12.0) | |
| High flow | 20 (29.4) | 10 (23.3) | 10 (40.0) | |
| NIVM or MV | 15 (22.1) | 3 (7.0) | 12 (40.0) | |
| Mechanic ventilation, days (median) | 5 (1–37) | 5 (5–5) | 3 (1–37) | 0.48 |
| Hospital stay, days | 6.5 (1–57) | 6 (1–48) | 7 (1–57) | 1.0 |
| Admission to ICU | 5.5 (1–48) | 7 (6–37) | 3 (1–37) | 0.62 |
| Stage | 0.002 | |||
| I-II | 43 (63.2) | 33 (76.7) | 10 (40.0) | |
| III-IV | 25 (36.8) | 10 (23.3) | 15 (60.0) |